After the market close on Sept. 4, Novartis reported that cardiometabolic drug pelacarsen missed its primary endpoint in its Lp(a)HORIZON trial. Separately, on Sept. 8, rare disease drug del-desiran missed its primary endpoint in the HARBOR trial in myotonic dystrophy type 1.
Novartis' research and development focuses on therapeutic areas that have historically been amenable to commercial innovation, including oncology, immunology, rare disease, and cardiology.
The company is undergoing declines in older drugs, including Entresto, Tasigna, and Promacta/Revolade.
|
Metric
|
NOVN
|
GSK
|
JNJ
|
|---|---|---|---|
Price/Earnings (Normalized) | 14.31 | 9.90 | 23.82 |
Price/Book Value | 6.69 | 4.04 | 7.33 |
Price/Sales | 5.06 | 2.16 | 6.44 |
Price/Cash Flow | 14.94 | 9.25 | 22.07 |
|
Metric
|
NOVN
|
GSK
|
JNJ
|
|---|---|---|---|
Quick Ratio | 0.55 | 0.52 | 0.73 |
Current Ratio | 0.86 | 0.82 | 1.09 |
Interest Coverage | 11.90 | 9.51 | 25.00 |
|
Metric
|
NOVN
|
GSK
|
JNJ
|
|---|---|---|---|
Return on Assets (Normalized) | 14.74% | 11.66% | 13.42% |
Return on Equity (Normalized) | 39.06% | 42.98% | 32.69% |
Return on Invested Capital (Normalized) | 21.25% | 22.63% | 20.33% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|ndcT?yG | LOCK|X^ | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|&WbX$< | LOCK|Qf | $623B | |||
| AbbVie Inc
ABBV
| LOCK|#X#mV? | LOCK|l? | $459B | |||
| Merck & Co Inc
MRK
| LOCK|^wZC%> | LOCK|Db& | $355B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|%BWt%v< | LOCK|C!x | $334B | |||
| Novartis AG ADR
NVS
| LOCK|s&XMVYl | LOCK|HF | $268B | |||
| AstraZeneca PLC
AZN
| LOCK|jBk!Y%K! | LOCK|h^ | $248B | |||
| Amgen Inc
AMGN
| LOCK|>b!n>%cn | LOCK|kR | $220B | |||
| Gilead Sciences Inc
GILD
| LOCK|&@!y<& | LOCK|?$ | $183B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|DC@!@D! | LOCK|JkV | $167B |
United States